Showing results (181-190 of 201) with videos related to
Sort By:
Pageof 21
Journal for Immunotherapy of Cancer|May 4, 2026
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcomaEvan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, et al.Journal for Immunotherapy of Cancer|April 19, 2024
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic diseaseJason J Luke, Diwakar Davar, Robert H Andtbacka, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal TumorsPing Chi, Li-Xuan Qin, Niedzica Camacho, et al.JNCI Cancer Spectrum|May 23, 2022
Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical TrialsNadine J McCleary, William S Harmsen, Ellana Haakenstad, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2021
Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II StudyOliver Zivanovic, Dennis S Chi, Qin Zhou, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2025
Circulating tumor DNA as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with advanced gastrointestinal stromal tumorsCiara M Kelly, Martina Bradic, Sara Saunds, et al.Journal for Immunotherapy of Cancer|June 13, 2025
Phase II study of rucaparib and nivolumab in patients with leiomyosarcomaSujana Movva, Kenneth Seier, Martina Bradic, et al.Melanoma Research|March 10, 2015
High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patientsKarin van den Hurk, Balazs Balint, Sinead Toomey, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2022
Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal TumorPing Chi, Li-Xuan Qin, Bastien Nguyen, et al.Journal for Immunotherapy of Cancer|July 25, 2025
Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumorsMohammed M Milhem, Trisha M Wise-Draper, Sunandana Chandra, et al.Pageof 21